| Title |
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
|
|---|---|
| Published in |
Investigational New Drugs, July 2019
|
| DOI | 10.1007/s10637-019-00830-3 |
| Pubmed ID | |
| Authors |
Marcus Noel, Eileen M. O’Reilly, Brian M. Wolpin, David P. Ryan, Andrea J. Bullock, Carolyn D. Britten, David C. Linehan, Brian A. Belt, Eric C. Gamelin, Bishu Ganguly, Donghua Yin, Tenshang Joh, Ira A. Jacobs, Carrie T. Taylor, Maeve A. Lowery |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 27% |
| China | 1 | 9% |
| Unknown | 7 | 64% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 73% |
| Scientists | 3 | 27% |
Mendeley readers
The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 79 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 15 | 19% |
| Student > Ph. D. Student | 10 | 13% |
| Student > Bachelor | 9 | 11% |
| Researcher | 8 | 10% |
| Other | 4 | 5% |
| Other | 6 | 8% |
| Unknown | 27 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 23% |
| Immunology and Microbiology | 9 | 11% |
| Biochemistry, Genetics and Molecular Biology | 8 | 10% |
| Agricultural and Biological Sciences | 5 | 6% |
| Nursing and Health Professions | 3 | 4% |
| Other | 5 | 6% |
| Unknown | 31 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 March 2022.
All research outputs
#6,365,268
of 25,775,807 outputs
Outputs from Investigational New Drugs
#282
of 1,266 outputs
Outputs of similar age
#104,044
of 361,730 outputs
Outputs of similar age from Investigational New Drugs
#4
of 26 outputs
Altmetric has tracked 25,775,807 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,266 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,730 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.